GlaxoSmithKline Pakistan Limited profits rise by 11.69 percent to Rs. 914.740 million

GlaxoSmithKline Pakistan Limited (GLAXO) today announced financial results for the three months period ending 31 March, 2018 reporting Sales at Rs. 9.122 billion; an increase of 8.74 percent. Furthermore, the company’s Gross Profit jumped to Rs. 2.657 billion during the outgoing three months.

On the expenses front, GLAXO reported 19.05 percent increase in Selling, Marketing and Distribution Expenses, 3.54 percent increase in Administrative Expenses, whereas, other operating expenses incurred by the company jumped 13.87 percent during the period.

Furthermore, GLAXO also reported a 38.63 percent decrease in Other Income reaching Rs. 53.203 million during the three months.

GlaxoSmithKline Pakistan Limited reported profit after taxation at Rs. 914.740 million against Rs. 819.031 million during the same period last year translating into an EPS of Rs. 2.87 vs. an EPS of Rs. 2.57 during the three months ending March, 2017. 

Comparison of Key Financials

Unconsolidated Profit and Loss Account – For the Three Months Ended, March 30th 2018

Key Financials

March, 2018

March, 2017

% Change

 

Amounts in PKR’ 000

Net Sales

9,122,557

8,388,948

8.74%

Cost of Sales

6,465,417

6,134,472

5.39%

Gross Profit

2,657,140

2,254,476

17.86%

Selling, Marketing and Distribution Expenses

888,423

746,263

19.05%

Administrative Expenses

246,939

238,498

3.54%

Other Operating Expenses

122,983

108,000

13.87%

Other Income

53,203

86,693

-38.63%

Operating Profit

1,451,998

1,248,408

16.31%

Financial Charges

49,151

4,212

1066.93%

Profit before Taxation

1,402,847

1,244,196

12.75%

Taxation

488,107

416,488

17.20%

PAT from continuing operations

914,740

827,708

10.51%

Loss after Taxation from discontinued operations

(8,677)

 

Total PAT

914,740

819,031

11.69%

EPS – Continuing Operations

2.87

2.60

10.38%

EPS – Discontinuing Operations

(0.03)

 

EPS

2.87

2.57

11.67%

Company release on Earnings Report can be accessed here.

Posted on: 2018-04-24T16:28:00+05:00